Anti-IL12RB1 antibodies
US11952417B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2021 |
| Grant date | Apr 9, 2024 |
| Priority date | — |
| Expiry date | Mar 3, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed towards isolated antibodies that bind to IL12Rβ1. Specifically, anti-IL12Rβ1 antibodies, and methods of treatment using the antibodies are disclosed. The antibody is targeted against the beta 1 subunit of the receptors of IL-12 and IL-23 and is capable of blocking signaling by inflammatory cytokines IL-12 and IL-23, which could be useful in treating autoimmune inflammatory diseases, such as inflammatory bowel disease (IBD), RA, and psoriasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.